Related Experiment Video
Updated: May 16, 2026
05:49
An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies
Published on: November 1, 2024
Emerging target-based paradigms to prevent and treat migraine
1Jefferson Headache Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. stephen.silberstein@jefferson.edu
Clinical Pharmacology and Therapeutics
|December 6, 2012
Summary
Migraine, a primary brain disorder, involves sensory processing and trigeminal nerve issues. Emerging treatments target calcitonin gene-related peptide (CGRP) and its receptor for effective migraine prevention.
Area of Science:
- Neurology
- Neuroscience
- Pharmacology
Background:
- Migraine is a primary brain disorder characterized by altered sensory modulation and trigeminal nerve dysfunction.
- The International Classification of Headache Disorders (ICHD-2) categorizes seven distinct migraine subtypes.
- Current treatment strategies encompass both acute and preventive approaches for managing migraine episodes.
Purpose of the Study:
- To review current and emerging therapeutic strategies for migraine management.
- To highlight novel targeted therapies and their mechanisms of action.
- To discuss the significance of recent advancements in migraine prevention, particularly antibody-based treatments.
Main Methods:
- Literature review of existing research on migraine pathophysiology and treatment.
- Analysis of newly developed targeted therapies, including receptor agonists and antagonists.
- Examination of recent developments in antibody therapies targeting calcitonin gene-related peptide (CGRP) pathways.
Main Results:
- Identification of several new targeted therapies, including 5-HT(1F) receptor agonists and calcitonin gene-related peptide (CGRP) antagonists.
- Inclusion of nitric oxide synthetase inhibitors and ion channel antagonists as novel treatment options.
- Significant advancement in preventive treatments through the development of antibodies targeting CGRP and its receptor.
Conclusions:
- The understanding of migraine pathophysiology has led to the development of innovative targeted therapies.
- New pharmacological agents offer improved treatment options for both acute and preventive migraine management.
- Antibody-based therapies targeting the CGRP pathway represent a significant breakthrough in migraine prevention.
Related Concept Videos
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:19Management of Insomnia
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...